Top Page
JOINN Laboratories (China) Co., Ltd. Class H
(6127)
JOINN Laboratories (China) Co., Ltd. Class H (6127) vs. iShares MSCI Hong Kong ETF (EWH)
JOINN Laboratories (China) Co., Ltd. Class H Business Overview & Revenue Model
JOINN Laboratories (China) Co., Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.67B | 2.02B | 2.38B | 2.27B | 1.52B | 1.08B |
| Gross Profit | 419.13M | 573.77M | 1.01B | 1.09B | 739.12M | 552.81M |
| EBITDA | 275.25M | 234.36M | 639.52M | 1.36B | 738.86M | 422.06M |
| Net Income | 225.08M | 74.08M | 396.99M | 1.07B | 557.46M | 315.01M |
Balance Sheet | ||||||
| Total Assets | 9.53B | 9.40B | 10.03B | 10.36B | 8.54B | 2.11B |
| Cash, Cash Equivalents and Short-Term Investments | 2.48B | 2.36B | 4.77B | 3.33B | 4.84B | 547.59M |
| Total Debt | 31.53M | 21.60M | 41.92M | 87.71M | 95.32M | 24.46M |
| Total Liabilities | 1.41B | 1.32B | 1.75B | 2.17B | 1.39B | 883.66M |
| Stockholders Equity | 8.12B | 8.08B | 8.28B | 8.18B | 7.14B | 1.22B |
Cash Flow | ||||||
| Free Cash Flow | 253.15M | 69.54M | 430.15M | 696.23M | 448.41M | 279.41M |
| Operating Cash Flow | 310.14M | 338.93M | 622.88M | 971.07M | 685.66M | 428.39M |
| Investing Cash Flow | -311.94M | -1.96B | ― | ― | ― | ― |
| Financing Cash Flow | -57.31M | -265.63M | -361.68M | ― | 5.29B | ― |
JOINN Laboratories (China) Co., Ltd. Class H Technical Analysis
JOINN Laboratories (China) Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$28.99B | 50.16 | 24.57% | 0.63% | 13.58% | 24.59% | |
69 Neutral | HK$342.85B | 21.64 | 25.65% | 1.84% | 11.55% | 64.46% | |
64 Neutral | HK$53.94B | 68.18 | 2.72% | 0.80% | -3.81% | -34.76% | |
61 Neutral | HK$32.68B | 78.27 | 2.74% | 0.15% | -21.76% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | HK$5.09B | -7.50 | -53.23% | ― | 29639.67% | 23.30% |
JOINN Laboratories (China) Co., Ltd. Class H Corporate Events
JOINN Laboratories (China) Co., Ltd. has issued a supplemental announcement detailing how it set the 2026 annual cap of RMB47 million for continuing connected transactions with Staidson under their research and development service framework agreement. The cap reflects anticipated non-clinical and clinical projects in 2026, historical transaction levels, labor and equipment costs, and JOINN’s capacity, with expected payments including both new 2026 projects and ongoing work from previous years; the size of these connected transactions triggers disclosure and annual review requirements under Hong Kong Listing Rules but does not require independent shareholders’ approval. The company also clarified the basis for a RMB16.5 million annual cap for 2026 services to be procured from BioAI, covering software development, automation, system integration, and digital/intelligent operations technical services, which is informed by JOINN’s expected project demand and BioAI’s service cost structure, underscoring increasing investment in digitalization alongside continued collaboration with related parties.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.
JOINN Laboratories (China) Co., Ltd. held its second extraordinary general meeting on December 5, 2025, where several key resolutions were approved. These included amendments to the Articles of Association, the dissolution of the supervisory committee, and the election of an employee director. The meeting saw participation from a significant number of shareholders, and the resolutions were passed with overwhelming support, indicating a strategic shift in the company’s governance structure.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$16.30 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.
JOINN Laboratories has announced the composition of its board of directors and their respective roles within various committees. This update reflects the company’s commitment to structured governance and strategic oversight, which may enhance its operational efficiency and strengthen its position in the competitive pharmaceutical and biotechnology sector.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$16.30 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.
JOINN Laboratories (China) Co., Ltd. has announced the renewal of its lease agreement with Biorichland for a property in northern California, extending the lease term to December 31, 2028. This transaction is classified as a connected transaction under Hong Kong Listing Rules, involving substantial shareholders and connected persons, and will be treated as an asset acquisition under IFRS 16.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$16.30 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.
JOINN Laboratories has entered into two significant agreements: the 2026 Staidson Research and Development Service Framework Agreement and the 2026 BioAI Service Framework Agreement. These agreements, effective from January 1, 2026, to December 31, 2026, involve continuing connected transactions with Staidson and BioAI, both associated with the company’s controlling shareholders. The transactions are subject to reporting and annual review requirements under the Listing Rules, indicating a strategic move to strengthen its service offerings and maintain compliance with regulatory standards.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$16.30 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.
JOINN Laboratories (China) Co., Ltd. has announced an Extraordinary General Meeting to be held on December 5, 2025, where shareholders will vote on several significant amendments to the company’s Articles of Association and corporate governance policies. Key proposals include the abolishment of the supervisory committee and updates to various management policies, indicating a strategic shift in governance and operational oversight. Additionally, the meeting will involve the election of new executive directors, which could impact the company’s leadership dynamics and future strategic direction.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$16.30 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.
JOINN Laboratories has announced a revision of annual caps for its 2024 Property Service Agreements with Beijing Joinn Biologics, reflecting an increase in transaction amounts due to rising demand for electricity and heating. The revised caps, set at RMB6 million for 2025 and RMB6.5 million for 2026, indicate a strategic adjustment to accommodate the company’s growing business needs, impacting its financial planning and compliance with Hong Kong’s Listing Rules.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$16.30 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.
JOINN Laboratories (China) Co., Ltd. has released its third quarterly report for 2025, revealing a significant decline in revenue and profits compared to the previous year. Despite a 34.87% decrease in revenue and an 81.85% drop in profits before income tax, the company reported a positive net cash flow from operating activities, indicating some operational resilience. The report highlights the challenges faced by the company in maintaining profitability, which may impact its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$16.30 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.
JOINN Laboratories (China) Co., Ltd. has announced proposed amendments to its Articles of Association and the rules of procedures for its general meeting of shareholders. These changes are in response to the upcoming amendments to the Company Law of the People’s Republic of China, effective from July 1, 2024. The key amendments include altering the number of directors on the board and removing the supervisory committee, aligning with legal and regulatory updates. These changes are expected to impact the company’s governance structure and could influence its operational efficiency and compliance with new legal standards.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$16.30 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.
JOINN Laboratories (China) Co., Ltd. has announced the proposed election of a new session of its board of directors as the current term is set to expire. All current board members have expressed their intention to stand for re-election at the upcoming extraordinary general meeting in 2025. This move is in line with the company’s governance practices and aims to ensure continuity in leadership. The re-elected directors will serve a three-year term, and their remuneration details will be disclosed in the company’s annual report.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$16.30 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.
JOINN Laboratories (China) Co., Ltd. has established a structured framework for its Audit Committee to enhance corporate governance and ensure compliance with relevant laws and regulations. The committee, composed of non-executive directors, is tasked with overseeing the company’s financial reporting, internal controls, and audit processes, thereby strengthening the company’s operational integrity and accountability.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$16.30 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.
JOINN Laboratories (China) Co., Ltd. has established a Nomination Committee under its Board of Directors to enhance its governance structure. This committee is tasked with selecting and recommending candidates for directors and senior management positions, ensuring a balanced and diverse board composition, and formulating selection criteria and procedures. This move is aimed at optimizing the board’s composition and improving the company’s governance, potentially impacting its operational efficiency and strategic decision-making.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$16.30 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.
JOINN Laboratories (China) Co., Ltd. has established a Remuneration and Evaluation Committee to enhance its governance structure by managing remuneration and evaluation for its directors and senior management. This committee is tasked with formulating assessment standards, reviewing remuneration policies, and ensuring transparent procedures for developing remuneration strategies, which could strengthen the company’s operational efficiency and align management incentives with corporate goals.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$16.30 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.
JOINN Laboratories has established a Strategic Development Committee under its Board of Directors to enhance its strategic development and investment decision-making processes. This initiative aims to improve the company’s core competitiveness and governance structure by focusing on long-term development strategies and major investment decisions, which are expected to positively impact its operations and industry positioning.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$16.30 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.
JOINN Laboratories (China) Co., Ltd. has announced that its board of directors will meet on 30 October 2025 to consider and approve the company’s third quarterly results for the nine months ending 30 September 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$14.30 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.